Australia markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
25.26+1.12 (+4.64%)
At close: 04:00PM EST
25.25 -0.01 (-0.04%)
After hours: 07:44PM EST
Full screen
Trade prices are not sourced from all markets
Previous close24.14
Bid25.02 x 1100
Ask25.27 x 800
Day's range23.11 - 25.29
52-week range9.53 - 70.29
Avg. volume1,477,955
Market cap1.769B
Beta (5Y monthly)1.77
PE ratio (TTM)N/A
EPS (TTM)-1.74
Earnings date28 Feb 2022 - 04 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est72.38
  • Zacks

    ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis

    Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.

  • GlobeNewswire

    ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis

    -- Launch Expected in H1 2022 -- SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. This approval follows the U.S. Food and Drug Administrati

  • Motley Fool

    Why ChemoCentryx Stock Tanked in 2021

    Shares of ChemoCentryx (NASDAQ: CCXI), a mid-cap biopharmaceutical company, fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence. ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels. Although the Food and Drug Administration (FDA) ultimately approved Tavneos on Oct. 8, 2021, the drug's fate was far from certain due to a mixed advisory committee (adcom) meeting earlier in the year.